Adamis Pharmaceuticals Provides Update on Clinical Study Assessing Tempol for the Treatment of COVID-19
14 mars 2022 08h17 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, March 14, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced that on March 11, 2022, the Data Safety Monitoring Board (DSMB) overseeing the Phase...
Adamis Pharmaceuticals Announces Retirement of Richard C. Williams, Chairman of the Board
04 mars 2022 07h30 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, March 04, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), today announced the retirement of Richard C. Williams, effective April 15, 2022. “Dick has...
Adamis Pharmaceuticals’ Clinical Study Assessing Tempol for the Treatment of COVID-19 Surpasses Enrollment Expectations
28 févr. 2022 07h30 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced that due to the acceleration of patient enrollment in the double-blind placebo...
Adamis Announces Inducement Option Grants Under Nasdaq Listing Rule 5635(c)(4)
18 févr. 2022 16h05 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a specialty biopharmaceutical company primarily focused on developing and commercializing products in...
Adamis Pharmaceuticals Provides Enrollment Update of Subjects in Phase 2/3 Study of Tempol for the Treatment of COVID-19
07 févr. 2022 09h17 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced the enrollment and dosing of more than 100 subjects in the Company’s ongoing Phase 2/3...
Adamis Pharmaceuticals Submits Fast Track Application to FDA for Tempol for the Treatment and Prevention of COVID-19
10 janv. 2022 07h30 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced the submission of a Fast Track Application to the U.S. Food and Drug Administration...
Adamis Pharmaceuticals Updates Comparative Pharmacology Model Data Supporting the Higher 5 mg Intramuscular Dose of Naloxone in ZIMHI™
01 déc. 2021 07h30 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced today that additional data in a quantitative systems pharmacology model supports the dose of...
Adamis Pharmaceuticals Regains Compliance with NASDAQ Continued Listing Requirements
23 nov. 2021 14h39 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid...
Adamis Pharmaceuticals Announces Third Quarter 2021 Financial Results and Provides Corporate Update
22 nov. 2021 16h47 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid...
Adamis Pharmaceuticals Schedules Financial Results Conference Call and Business Update
19 nov. 2021 15h34 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid...